HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS - Free Report) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $27.00 price objective on the stock.
Several other equities analysts have also recently commented on EOLS. Barclays boosted their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, September 13th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Evolus in a report on Friday, September 13th.
View Our Latest Report on EOLS
Evolus Stock Up 2.6 %
NASDAQ EOLS traded up $0.43 during trading on Friday, reaching $16.75. 374,201 shares of the company's stock were exchanged, compared to its average volume of 578,875. The firm has a market capitalization of $1.06 billion, a PE ratio of -18.41 and a beta of 1.31. Evolus has a fifty-two week low of $7.67 and a fifty-two week high of $17.82. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The company's fifty day simple moving average is $16.23 and its 200-day simple moving average is $13.67.
Evolus (NASDAQ:EOLS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). The company had revenue of $66.91 million for the quarter, compared to analysts' expectations of $65.06 million. Sell-side analysts predict that Evolus will post -0.64 EPS for the current year.
Insider Buying and Selling
In other news, CFO Sandra Beaver sold 3,276 shares of the firm's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares of the company's stock, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now owns 82,375 shares of the company's stock, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Evolus
A number of institutional investors have recently bought and sold shares of EOLS. Quest Partners LLC bought a new position in shares of Evolus during the 2nd quarter worth approximately $43,000. Quarry LP bought a new position in shares of Evolus during the second quarter valued at $54,000. Profund Advisors LLC acquired a new stake in shares of Evolus in the 2nd quarter valued at $130,000. Arizona State Retirement System grew its holdings in shares of Evolus by 9.4% in the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock worth $158,000 after purchasing an additional 1,253 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company's stock valued at $162,000 after purchasing an additional 1,035 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
